Yissum - Research Development Company of the Hebrew University

Novel Bile Acid Conjugates for Treatment of NAFLD/NASH and Obesity

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Novel Bile Acid Conjugates for Treatment of NAFLD/NASH and Obesity
Project ID : 7-2011-2563

Description of the technology

Categories

Fatty liver, metabolic syndrome, obesity

Development Stage

Drug at preclinical stage

Background

  • Fatty liver disease - Non alcoholic fatty liver disease (NAFLD) isa continuum of diseases that include simple steatosis and non-alcoholic steatohepatitis (NASH) ultimately leading to cirrhosis, hepatocellular carcinoma (HCC) and/or end stage liver failure which develop in the absence of excessive alcohol intake. NAFLD affects 30% of the general population and 70-80% of diabetic and obesity patients. Simple steatosis is most often considered to have a benign hepatic pathological prognosis. NASH, as oppose to steatosis is pathologically characterized by the presence of steatosis and inflammation, and is related to higher morbidity and mortality. NASH is accounted for liver related complications, and it is one of the leading causes of liver transplantation.
  • Obesity - Worldwide obesity has nearly doubled since 1980. In 2008, more than 1.4 billion adults were overweight. Of these over 200 million men and nearly 300 million women were obese. 35% of adults aged 20 and over were overweight in 2008, and 11% were obese. More than 40 million children under the age of five were overweight in 2011 (World Health Organization). The prevalence of obesity today varies nearly tenfold among OECD countries, from a low of 2.1% in India, to 30% or more in the United States and Mexico (OECD obesity update 2012).

Our Innovation

  • The aim of this project is to develop a novel bile acid related small molecule that can be used to treat NAFLD and NASH. For that reason we have synthesized an Arginine-bile acid conjugate (CDCArg) that was tested in animal nutritional models of NAFLD and obesity.
  • The compound is highly effective in preventing nutritional-induced NASH/NAFLD
  • The compound is highly effective in treating nutrition-induced NASH/NAFLD
  • The compound was effective in lowering body weight of obese high fat diet fed mice.
  • Mechanism of action elucidated

Key Features

  • A novel, orally administered, treatment for NAFLD and obesity
  • Non-toxic
  • Significantly lowering lipids absorption with no effect on protein absorption

Development Milestones

  • Modifying molecules in order to develop a second generation compounds with optimized potency.
  • Exploring other possible mechanisms of action
  • Combination with other drugs (optional)
  • Moving forward towards human clinical trials

The Opportunity

  • Huge potential market.
  • Unmet medical need.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Zecharia Madar
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
Biochemistry, Food Science and Nutrition

Oren Tirosh
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
Biochemistry, Food Science and Nutrition

Shlomo Sasson
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • metabolic

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.